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INTRODUCTION
Congenital complete atrioventricular block (CCAVB)
is a rare, potentially lethal disease with an estimated
incidence of 1 every 15,000 to 20,000 live births (1). A
recent  comparative  study  conducted  in  Finland
demonstrated  an  increasing  incidence  from  1  to
25,000 to 1 to 11,000 during the last decades; possi-
ble explanations are the enhanced neonatal care and
also that the better diagnostic methods allow more an-
tenatal diagnosis, and moreover, the increasing num-
ber of mothers with connective tissue disease with
successful delivery (2).
Nowadays, the diagnosis can be made in utero as
early as between week 16 and 28 of gestation by fetal
echocardiography. Aim of this review is to delineate the
current knowledge on CCAVB presenting in children
without structural heart disease: etiology, outcome,
management and which are still the open problems.
Aetiology and outcome
There are two kinds of congenital heart block in
structurally normal hearts: the first one is usually diag-
nosed in utero and is associated with the circulating
maternal anti-Sjögren Syndrome A and anti-Sjögren
Syndrome B antibodies (anti-SS-A/Ro and anti-SS-
B/La ribonucleoproteins antibodies) (3-5). The other
kind of CCAVB is detected later in the neonatal period
or during infancy or childhood, and there is no clear as-
sociation with maternal antibodies as in the first kind
(4, 6).
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The first demonstration of a correlation between ma-
ternal systemic lupus erythematosus (SLE) and CCAVB
was described in 1977 (7); subsequently the association
between the presence of maternal anti SS-A/Ro and an-
ti SS-B/La and the development of a CCAVB was con-
firmed and tested in many series (6,8). The pathological
changes have been strictly correlated to the presence of
circulating Anti SS-A/Ro alone or in conjunction with
Anti SS-B/La even in mothers without clinical manifes-
tations of connective disease ( SLE, Sjögren’s syn-
drome, rheumatoid arthritis, mixed connective disease).
The signature histologic pattern of autoimmune CCAVB
is fibrous replacement of the conducting tissue and,
sometimes, of the surrounding myocardium, but also a
fibroelastosis replacement and widespread dystrophic
calcifications in several areas have been reported (5, 9).
The immuno-histology of hearts from fetuses/neonates
with CCAVB demonstrated the presence of an exagger-
ated apoptosis and macrophage infiltrates resulting in a
progressive scarring. The mechanisms by which mater-
nal antibodies initiate and finally eventuate the fibrotic
transformation are not clear (5); moreover, a recent re-
port suggests that transplacental transfer of maternal
cells  during  the  pregnancy  creates  a  state  of  mi-
crochimerism that may concur to the pathogenesis of
cardiac injury in neonatal lupus. Associations between
maternal HLA, not fetal HLA, and the CCAVB in the fe-
tus, in presence of maternal immune disease, have
been also described (10).  
Third  degree  atrioventricular  block  seems  irre-
versible, but the widespread use of fetal echocardiogra-
phy also helps in diagnosis of first and second degree
blocks in utero, opening a possibility of treatment. How,
ever, it seems that incomplete AV block progresses to
complete block post-natally despite the clearance of
maternal antibodies from neonatal circulation (3). Re-
cent reports suggest a direct role of maternal autoanti-
bodies in inhibition of inward current calcium channels,
and the presence of sinus bradycardia (SB) was identi-
fied, in an animal model, as a potential marker in detec-
tion and prevention of CCAVB (11) confirming clinical
data  correlating  SB  in  infants  born  with  mothers
seropositive to anti SSA/Ro (12).
The immunologic basis of CCAVB can explain the de-
velopment of dilated cardiomyopathy despite pacing; it
seems  that  in  up  to  15%  of  cases  a  myocardi-
tis/endocarditis occurs post-natally even after ten years
(13, 14). 
Echocardiography allows the in utero diagnosis and
follow-up of CCAVB. The fetus may remain asympto-
matic adjusting its stroke volume in order to compen-
sate the bradycardia or may develop cardiac failure and
intrauterine hydrops (15).
The mortality in infants with isolated CCAVB is esti-
mated between 8 and 16% and between 4 and 8% in
children and adults (1, 16). The mortality and morbidity
of patients diagnosed outside the neonatal period is
significantly lower than those with an in utero diagnosis
(mortality of 5% vs 19% at a mean follow-up age of 22
years); early infancy seems the period of greatest risk of
death (17).
Risk factors for worse outcome in CCAVB are fetal di-
agnosis, the presence of hydrops fetalis, delivery at ￿ 32
weeks gestation, and a ventricular rate <55 beats/min in
early pregnancy (13, 18). Fetal hydrops was associated
with a fetal and neonatal mortality between 83 and
100% in various reports and the coexistence of hydrops
and endocardial fibroelastosis strongly predicts a worse
prognosis (18).  
Up to 50% of asymptomatic patients during child-
hood will complain of symptoms in adulthood and 10%
will die prematurely; they could have the fatal event dur-
ing their first Adams-Stokes episode (19, 20). A mean
daytime heart rate < 50 beats/min has been reported as
a risk factor for sincope and sudden death; moreover
frequent episodes of junctional exit block, flat junction-
al response or tachyarrhythmias were present in pa-
tients who developed worse outcome (21). 
In one report of 102 patients with CCAVB only 11% of
neonatal and 12% of childhood patients had not re-
quired a pacemaker implant by the age of 20 years (13).
Another negative prognostic sign is the presence of a
prolonged QTc that has been reported in 7-22% of pa-
tients with CCAVB (20). In a recent report the overall
morbidity of patients who survived is 17%; the pres-
ence of a dilated cardiomyopathy concurs to a worse
outcome with a mortality rate of 75% (17). 
Management and therapeutic options
Usually,  the  in  utero diagnosis  comes  from  the
echocardiographic recognition of fetal bradycardia ob-
serving the difference in atrioventricular valve opening
or ventricular activity in comparison to a higher atrialVitali Serdoz and Cappato
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rate (22).
The diagnosis in infancy and in childhood is not easy;
in infancy a symptomatic bradycardia can manifest with
poor growth and development, sometimes with sleep
disorders such as nightmares and the need for frequent
naps, or just simply with a sedentary attitude. 
Several studies report in utero therapy with sympa-
thomimetics, digitalis and steroids (4, 23, 24) in order
to increase the heart rate, to reduce with digitalis both
the heart failure and hydrops despite the AV block and
to reduce the circulating maternal antibodies with
steroids. Digoxin seems safe and represents a thera-
peutic option if the fetus presents with cardiac failure
(23). Even if β-sympathomimetics can cause myocar-
dial ischemia and pulmonary edema and sometimes
the dosages needed to increase fetal heart rate are
not tolerated by the mothers, the administration of
maternal salbutamol can be an option in case of se-
vere fetal bradycardia (24). Some positive effects
have been registrated in fetus with heart rate <55
beats/min with the maternal assumption of terbutaline
every 4-6 hours (25, 26).
In a recent study the maternal assumption of corti-
costeroids was evaluated in presence of Anti SS-
A/Ro, prior or after the 16th week of gestation: none of
the neonates treated before the 16th week developed
CCAVB compared to the 25% of neonates whose
mothers were not treated or treated after the 16th
week (27).
Nowadays, pacemaker (PM) implantation has a piv-
otal role in management and therapy of CCAVB; even
if eventually the patients will receive a PM, timing of
implant depends strongly on symptoms and some-
times it is still controversial (28, 29). 
In neonates with isolated CCAVB, the implant of a
PM is recommended with a heart rate lower than 55
beats/min or if heart failure develops (30).
A recent study (16) identified the following indica-
tions for PM therapy: syncope, heart failure, left ven-
tricular dilation, mitral valve regurgitation, unstable
escape rhythm, inappropriate sinus tachycardia, a
prolonged QT interval, presence of ventricular ar-
rhythmias and a daytime bradycardia (<55bpm) in in-
fants. In this study the PM therapy reduces both mor-
bidity and mortality in children with CCAVB with and
without cardiac malformation when compared to nat-
ural history data.
In addition, a prophylactic pacemaker treatment
could be recommended in adolescents and young
adults with CCAVB who are asymptomatic to prevent
Adams-Stokes attacks and sudden death (31).
When the pediatric cardiologists decide the timing
of PM implantation they need to evaluate also many
technical elements. In the last two decades PM thera-
py in children has considerably improved mainly due
to new generation generators, that are smaller, and to
better leads, but in any case the morbidity and the ne-
cessity of reoperation and lead extraction still remain
(16, 28, 30). Nowadays, the trend is towards a surgical
approach in neonates and in prematures, implanting
epicardial leads and especially steroid-eluting epicar-
dial leads that demonstrated a longer longevity and a
better threshold. The transvenous approach seems
safe in children of 4-5 years of age with weight >10-20
kg; in infants and smaller children the diameter of in-
nominate vein and superior vena cava is too small and
there is the risk of occlusion (19, 30). Some centers
are evaluating the implant of new smaller leads also in
little children from both internal jugular and subcla-
vian venous approach (32).
The PM generator is usually positioned in the ab-
dominal wall with the epicardial lead surgical ap-
proach, and in a subpectoralis pocket if the transve-
nous approach is preferred. A typical problem with
children is the out-growth of leads as the children
grow up: the lead length should always be redundant
in order to allow the out-growth of leads. Some au-
thors suggest that the best positioning for the ventric-
ular lead seems in the right ventricular outflow tract,
because in children the heart grows in the long axis
more than in short axis (19).
In children older than 3 years of age the double lead
PM implant with a DDD mode is becoming more com-
mon (17). The DDD mode should be preferred in pa-
tients with sinus node dysfunction and some authors
suggest the DDD mode in order to maintain the AV
synchrony (33) although  no definite evidence sup-
ports a preference for DDD mode versus single pacing
lead (17, 28). Single pacing lead systems are well tol-
erated in children where VVIR mode responds ade-
quately to their physiological needs and the incidence
of pacemaker syndrome is low (17, 19, 34).
The follow-up of children with congenital complete
heart block should include a complete clinical and in-Congenital complete atrioventricular block in the early pediatric population
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strumental evaluation (ECG, Holter ECG monitoring
and treadmill exercise test for heart rate and pauses
evaluation, and echocardiogram in order to assess
ventricular dimensions and function). As many au-
thors suggest, the decision to implant a PM in an
asymptomatic  patient  depends  on  the  patient’s
lifestyle, body size and on relative PM indications;
when an adolescent reaches adult body size the ben-
efit of the pacemaker in prevention of sudden death
overweighs the risks of the implantation so the prob-
lem is to decide the proper timing of the implant (16,
17, 19, 35).
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